Navidea Biopharmaceuticals, Inc.
NAVB · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $0 | $1 | $1 | $0 |
| % Growth | -87.6% | -41.9% | 3,337.6% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | $0 | $1 | $0 |
| % Margin | -259.4% | 62.6% | 99.9% | 75% |
| R&D Expenses | $6 | $5 | $5 | $5 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $8 | $7 | $7 | $6 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | -$0 | $0 | -$1 |
| Operating Expenses | $14 | $12 | $12 | $11 |
| Operating Income | -$14 | -$12 | -$11 | -$11 |
| % Margin | -21,402.1% | -2,269.1% | -1,170.6% | -41,184.6% |
| Other Income/Exp. Net | -$1 | $0 | -$0 | $0 |
| Pre-Tax Income | -$15 | -$12 | -$11 | -$11 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$15 | -$12 | -$11 | -$11 |
| % Margin | -23,117.6% | -2,207.1% | -1,171.8% | -41,120.9% |
| EPS | -0.59 | -0.4 | -0.48 | -0.76 |
| % Growth | -47.5% | 16.7% | 36.8% | – |
| EPS Diluted | -0.56 | -0.4 | -0.48 | -0.76 |
| Weighted Avg Shares Out | 29 | 29 | 24 | 14 |
| Weighted Avg Shares Out Dil | 31 | 29 | 24 | 14 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$14 | -$12 | -$11 | -$11 |
| % Margin | -21,298.7% | -2,164.9% | -1,162.9% | -40,641.7% |